Quillet Alexandre, Colin Olivier, Bourgeois Nicolas, Favrelière Sylvie, Ferru Aurélie, Boinot Laurence, Lafay-Chebassier Claire, Perault-Pochat Marie-Christine
Service de Pharmacologie Clinique et Vigilances, CHU de Poitiers, 2 rue de la milétrie, 86021, Poitiers, France.
Service de Neurologie, CHU de Poitiers, 2 rue de la milétrie, 86021, Poitiers, France.
Fundam Clin Pharmacol. 2018 Apr;32(2):227-233. doi: 10.1111/fcp.12333. Epub 2017 Nov 27.
The aim of this study was to assess an automated detection method of serious adverse reactions induced by oral targeted therapy (OTT) in patients with cancer, performed in the French Diagnosis Related Groups (DRG) database. Patients with cancer of the Poitiers hospital who started an OTT between 2014 and 2015 were included. This study focused on adverse drug reaction which required inpatient hospitalization (ADR ). All diagnoses coded in the DRG database for hospital stays that occurred within 3 months after OTT initiation were collected (potential ADR ). Filters (exclusion criteria) were automatically applied on potential ADR to exclude diagnoses that were not adverse drug reactions (false positives). A pharmacovigilance review was carried out to identify ADR in the medical records (reported ADR ). The sensitivity and specificity of the detection method were estimated for each filter combinations by comparison between potential and reported ADR . This study included 129 patients. The medical records review led to identify 19 ADR (all coded in the DRG database) in 14 patients. To maintain a 100% sensitivity of the method detection, the best specificity obtained was 58.3% (95% IC: [55.2-61.4]).The use of restrictive filters ('drug' in the diagnostic label, specific diagnosis code for adverse cancer drug reaction) resulted in a 97.8% specificity (95% IC: [96.6-98.5]) with a 38.2% sensitivity (95% IC: [23.9-55.0]). Our method has detected the third of ADR with an excellent specificity. Complementary experimentations in pharmacovigilance centers are necessary to evaluate the interest of this tool in routine in addition to spontaneous reporting.
本研究旨在评估在法国诊断相关组(DRG)数据库中执行的一种用于检测癌症患者口服靶向治疗(OTT)引起的严重不良反应的自动化检测方法。纳入了2014年至2015年间在普瓦捷医院开始接受OTT治疗的癌症患者。本研究聚焦于需要住院治疗的药物不良反应(ADR)。收集了OTT开始后3个月内住院期间DRG数据库中编码的所有诊断(潜在ADR)。对潜在ADR自动应用筛选器(排除标准)以排除非药物不良反应的诊断(假阳性)。进行了药物警戒审查以在病历中识别ADR(报告的ADR)。通过比较潜在ADR和报告的ADR,估计每种筛选器组合的检测方法的敏感性和特异性。本研究纳入了129名患者。病历审查在14名患者中识别出19例ADR(均在DRG数据库中编码)。为保持方法检测的100%敏感性,获得的最佳特异性为58.3%(95%置信区间:[55.2 - 61.4])。使用限制性筛选器(诊断标签中的“药物”、癌症药物不良反应的特定诊断代码)导致特异性为97.8%(95%置信区间:[96.6 - 98.5]),敏感性为38.2%(95%置信区间:[23.9 - 55.0])。我们的方法以优异的特异性检测出了三分之一的ADR。除自发报告外,还需要在药物警戒中心进行补充实验以评估该工具在常规应用中的价值。